Operator: Good afternoon and welcome to the EQRx First Quarter 2023 Financial Results Conference Call. Please be advised that this conference call is being recorded.
EQRx, Inc. (NASDAQ:EQRX), a pharmaceutical company based in the United States, produces medications primarily for treating cancer and immune-inflammatory diseases.
Initiated a U.S.-led, comparative Phase 3b clinical trial with aumolertinib for the first-line treatment of EGFR-mutated NSCLCAnnounced U.K. MHRA acceptance of EQRx's first regulatory submission (aumolertinib)